Dry Eye

Vevizye was approved by the US FDA under the name Vevye in May 2023 for the treatment of moderate to severe dry eye disease.

The latest in market trends can offer insights into patient care.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser in a news release.

Increased pressure and inflammation require prompt treatment to avoid complications.

The collaboration agreement will allow the two companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.

Perfluorohexyloctane may slow evaporation to reduce dry eye.

Exploring strategies for effective management of a multifaceted condition.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The solution, CAM360 AmnioGraft, is hydrated and shelf-stable without need for refrigeration.

The trial, in part of the ASTRO study, will evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment 0.5%.

One of the resources provided by the partnership is a Dry Eye Wheel, which provides mitigation, measurement, and management processes to inform the treatment of dry eye disease.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The novel therapy for dry eye is a cross-linked hyaluronic acid derivative cleared by the FDA.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

The Tono-Vera Tonometer allows for automated IOP measurements and eliminates the need for a topical anesthetic.

Providing prevention strategies can keep patients comfortable during allergy season.

The microemulsion drug ocular penetration system platform technology was found to effectively formulate and deliver lipophilic molecules via topical eye drops.

Preventive options should be as important as treating symptoms

The diagnostic aid platform, C.DIAG, utilizes artificial intelligence to assist with the diagnosis and treatment of dry eye disease.

The nutritional supplement comprised of a proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 improved tear production, tear film break-up time, and tear osmolarity, among others.

UC Berkeley’s Herbert Wertheim School of Optometry and Vision Science integrated the new laser in the beginning of March in its dry eye clinic for treatment of meibomian gland dysfunction.

Evaluating and managing lid margin disease and meibomian gland dysfunction.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.

Warm compresses are an invaluable step in the treatment of dry eye.

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.